Puma Biotechnology, Inc. (NASDAQ:PBYI) Shares Bought by BNP Paribas Financial Markets

BNP Paribas Financial Markets lifted its stake in Puma Biotechnology, Inc. (NASDAQ:PBYI) by 2,002.5% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 67,702 shares of the biopharmaceutical company’s stock after acquiring an additional 64,482 shares during the quarter. BNP Paribas Financial Markets owned 0.14% of Puma Biotechnology worth $173,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in the business. Rice Hall James & Associates LLC increased its position in shares of Puma Biotechnology by 3.3% during the second quarter. Rice Hall James & Associates LLC now owns 144,792 shares of the biopharmaceutical company’s stock worth $472,000 after purchasing an additional 4,686 shares in the last quarter. Patriot Financial Group Insurance Agency LLC raised its position in Puma Biotechnology by 72.7% in the third quarter. Patriot Financial Group Insurance Agency LLC now owns 19,000 shares of the biopharmaceutical company’s stock worth $48,000 after acquiring an additional 8,000 shares in the last quarter. Royce & Associates LP increased its holdings in Puma Biotechnology by 71.8% in the third quarter. Royce & Associates LP now owns 20,165 shares of the biopharmaceutical company’s stock valued at $51,000 after buying an additional 8,427 shares in the last quarter. Squarepoint Ops LLC boosted its stake in shares of Puma Biotechnology by 17.7% during the 2nd quarter. Squarepoint Ops LLC now owns 71,391 shares of the biopharmaceutical company’s stock worth $233,000 after acquiring an additional 10,757 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new position in Puma Biotechnology during the third quarter worth about $34,000. 61.29% of the stock is currently owned by institutional investors and hedge funds.

Puma Biotechnology Price Performance

NASDAQ:PBYI opened at $2.92 on Wednesday. Puma Biotechnology, Inc. has a 52-week low of $2.22 and a 52-week high of $7.73. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.40 and a current ratio of 1.42. The stock’s 50-day simple moving average is $2.94 and its 200 day simple moving average is $3.02. The company has a market cap of $143.34 million, a P/E ratio of 6.08 and a beta of 1.08.

Puma Biotechnology (NASDAQ:PBYI) last released its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported $0.41 earnings per share for the quarter, beating analysts’ consensus estimates of $0.31 by $0.10. The company had revenue of $80.50 million during the quarter, compared to the consensus estimate of $71.32 million. Puma Biotechnology had a net margin of 9.56% and a return on equity of 41.60%. During the same period in the previous year, the business earned $0.12 earnings per share. As a group, sell-side analysts forecast that Puma Biotechnology, Inc. will post 0.31 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently commented on PBYI shares. HC Wainwright restated a “buy” rating and issued a $7.00 price objective on shares of Puma Biotechnology in a report on Wednesday, November 20th. StockNews.com lowered Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research report on Friday, December 6th.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.